The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles
Open accessAbstract
Increasing reports of antimicrobial resistance and limited new antibiotic discoveries and development have fuelled innovation in other research fields and led to a revitalization of bacteriophage (phage) studies in the Western world. Phage therapy mainly utilizes obligately lytic phages to kill their respective bacterial hosts, while leaving human cells intact and reducing the broader impact on commensal bacteria that often results from antibiotic use. Phage therapy is rapidly evolving and has resulted in cases of life-saving therapeutic use and multiple clinical trials. However, one of the biggest challenges this antibiotic alternative faces relates to regulations and policy surrounding clinical use and implementation beyond compassionate cases. This review discusses the multi-drug resistant Gram-negative pathogens of highest critical priority and summarizes the current state-of-the-art in phage therapy targeting these organisms. It also examines phage therapy in humans in general and the approaches different countries have taken to introduce it into clinical practice and policy. We aim to highlight the rapidly advancing field of phage therapy and the challenges that lie ahead as the world shifts away from complete reliance on antibiotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142
Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?
de Kraker, M. E. A., Stewardson, A. J., & Harbarth, S. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002184 · Cited by 1,596
Establishment of infection: lessons from a versatile opportunist
Lyczak, J. B., Cannon, C. L., & Pier, G. B. (2000) · Microbes and Infection · doi:10.1016/s1286-4579(00)01259-4 · Cited by 1,341
Pseudomonas aeruginosa: all roads lead to resistance
Breidenstein, E. B. M., de la Fuente-Núñez, C., & Hancock, R. E. W. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.04.005 · Cited by 1,286
Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00954-17 · Cited by 1,254
Wright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01973.x · Cited by 864
Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa
Chan, B. K., Sistrom, M., Wertz, J. E., Kortright, K. E., Narayan, D., & Turner, P. E. (2016) · Scientific Reports · doi:10.1038/srep26717 · Cited by 715
Phage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models
McConnell, M. J., Actis, L., & Pachón, J. (2013) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2012.00344.x · Cited by 540
Sarker, S. A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton, F., Bourdin, G., McCallin, S., Ngom-Bru, C., Neville, T., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.12.023 · Cited by 533
Phage treatment of an aortic graft infected with Pseudomonas aeruginosa
Chan, B. K., Turner, P. E., Kim, S., Mojibian, H. R., Elefteriades, J. A., & Narayan, D. (2018) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eoy005 · Cited by 501
Roach, D. R., Leung, C. Y., Henry, M., Morello, E., Singh, D., Di Santo, J. P., Weitz, J. S., & Debarbieux, L. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.06.018 · Cited by 484
Molecular and Evolutionary Determinants of Bacteriophage Host Range
de Jonge, P. A., Nobrega, F. L., Brouns, S. J. J., & Dutilh, B. E. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.08.006 · Cited by 475
Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial
Rhoads, D. D., Wolcott, R. D., Kuskowski, M. A., Wolcott, B. M., Ward, L. S., & Sulakvelidze, A. (2009) · Journal of Wound Care · doi:10.12968/jowc.2009.18.6.42801 · Cited by 468
Clinical Aspects of Phage Therapy
Międzybrodzki, R., Borysowski, J., Weber-Dąbrowska, B., Fortuna, W., Letkiewicz, S., Szufnarowski, K., Pawełczyk, Z., Rogóż, P., Kłak, M., Wojtasik, E., et al. (2012) · Advances in Virus Research · doi:10.1016/b978-0-12-394438-2.00003-7 · Cited by 373
Pirnay, J.-P., Verbeken, G., Ceyssens, P.-J., Huys, I., De Vos, D., Ameloot, C., & Fauconnier, A. (2018) · Viruses · doi:10.3390/v10020064 · Cited by 347
Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach
Bassetti, M., Poulakou, G., Ruppe, E., Bouza, E., Van Hal, S. J., & Brink, A. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4878-x · Cited by 277
Quality and Safety Requirements for Sustainable Phage Therapy Products
Pirnay, J.-P., Blasdel, B. G., Bretaudeau, L., Buckling, A., Chanishvili, N., Clark, J. R., Corte-Real, S., Debarbieux, L., Dublanchet, A., De Vos, D., et al. (2015) · Pharmaceutical Research · doi:10.1007/s11095-014-1617-7 · Cited by 276
Lood, R., Winer, B. Y., Pelzek, A. J., Diez-Martinez, R., Thandar, M., Euler, C. W., Schuch, R., & Fischetti, V. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04641-14 · Cited by 272
Forti, F., Roach, D. R., Cafora, M., Pasini, M. E., Horner, D. S., Fiscarelli, E. V., Rossitto, M., Cariani, L., Briani, F., Debarbieux, L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02573-17 · Cited by 269
A century of phage research: Bacteriophages and the shaping of modern biology
Keen, E. C. (2015) · BioEssays · doi:10.1002/bies.201400152 · Cited by 242
Phage Therapy for a Multidrug-Resistant Acinetobacter baumannii Craniectomy Site Infection
LaVergne, S., Hamilton, T., Biswas, B., Kumaraswamy, M., Schooley, R. T., & Wooten, D. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy064 · Cited by 239
Treatment of experimental infections of mice with bacteriophages
SOOTHILL, J. S. (1992) · Journal of Medical Microbiology · doi:10.1099/00222615-37-4-258 · Cited by 220
Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens
Burrowes, B., Harper, D. R., Anderson, J., McConville, M., & Enright, M. C. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.90 · Cited by 218
Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa
Waters, E. M., Neill, D. R., Kaman, B., Sahota, J. S., Clokie, M. R. J., Winstanley, C., & Kadioglu, A. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209265 · Cited by 212
Pharmacokinetic Principles of Bacteriophage Therapy
Payne, R. J. H., & Jansen, V. A. A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00002 · Cited by 207
A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa
Guo, M., Feng, C., Ren, J., Zhuang, X., Zhang, Y., Zhu, Y., Dong, K., He, P., Guo, X., & Qin, J. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00293 · Cited by 190
Regeimbal, J. M., Jacobs, A. C., Corey, B. W., Henry, M. S., Thompson, M. G., Pavlicek, R. L., Quinones, J., Hannah, R. M., Ghebremedhin, M., Crane, N. J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02877-15 · Cited by 187
Contribution of the Immune Response to Phage Therapy
Krut, O., & Bekeredjian-Ding, I. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701745 · Cited by 172
Fong, S. A., Drilling, A., Morales, S., Cornet, M. E., Woodworth, B. A., Fokkens, W. J., Psaltis, A. J., Vreugde, S., & Wormald, P.-J. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00418 · Cited by 164
Safety and efficacy of phage therapy via the intravenous route
Speck, P., & Smithyman, A. (2016) · FEMS Microbiology Letters · doi:10.1093/femsle/fnv242 · Cited by 160
Cao, F., Wang, X., Wang, L., Li, Z., Che, J., Wang, L., Li, X., Cao, Z., Zhang, J., Jin, L., et al. (2015) · BioMed Research International · doi:10.1155/2015/752930 · Cited by 159
Chadha, P., Katare, O. P., & Chhibber, S. (2017) · Burns · doi:10.1016/j.burns.2017.03.029 · Cited by 158
Phage Therapy: What Have We Learned?
Górski, A., Międzybrodzki, R., Łobocka, M. B., Głowacka-Rutkowska, A., Bednarek, A., Borysowski, J., Jończyk‐Matysiak, E., Łusiak-Szelachowska, M., Weber‐Dąbrowska, B., Bagińska, N., et al. (2018) · Viruses · doi:10.3390/v10060288 · Cited by 157
Kumari, S., Harjai, K., & Chhibber, S. (2010) · Journal of Medical Microbiology · doi:10.1099/jmm.0.018580-0 · Cited by 149
Thandar, M., Lood, R., Winer, B. Y., Deutsch, D. R., Euler, C. W., & Fischetti, V. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02972-15 · Cited by 145
Leitner, L., Sybesma, W., Чанішвілі, Н., Goderdzishvili, M., Chkhotua, A. B., Ujmajuridze, A., Schneider, M. P., Sartori, A. M., Mehnert, U., Bachmann, L. M., et al. (2017) · BMC Urology · doi:10.1186/s12894-017-0283-6 · Cited by 144
The role of regulated clinical trials in the development of bacteriophage therapeutics
Parracho, H. M. R. T., Burrowes, B. H., & Enright, M. C. (2012) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000050 · Cited by 133
Bacteriophage therapy: a regulatory perspective
Pelfrene, E., Willebrand, E., Sanches, A., Sebris, Z., & Cavaleri, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw083 · Cited by 133
Chang, R. Y. K., Wong, J., Mathai, A., Morales, S., Kutter, E. M., Britton, W. J., Li, J., & Chan, H. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.09.002 · Cited by 117
The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-Lactams
Dufour, N., Delattre, R., Ricard, J.-D., & Debarbieux, L. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix184 · Cited by 112
In vitro characterization of PlyE146, a novel phage lysin that targets Gram-negative bacteria
Larpin, Y., Oechslin, F., Moreillon, P., Resch, G., Entenza, J. M., & Mancini, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192507 · Cited by 111
Call for a Dedicated European Legal Framework for Bacteriophage Therapy
Verbeken, G., Pirnay, J., Lavigne, R., Jennes, S., Vos, D. D., Casteels, M., & Huys, I. (2014) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-014-0269-y · Cited by 107
Chhibber, S., Nag, D., & Bansal, S. (2013) · BMC Microbiology · doi:10.1186/1471-2180-13-174 · Cited by 105
Peng, S.-Y., You, R.-I., Lai, M., Lin, N., Chen, L., & Chang, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-11832-7 · Cited by 105
Chang, R. Y. K., Chen, K., Wang, J., Wallin, M., Britton, W. J., Morales, S., Kutter, E. M., Li, J., & Chan, H. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01714-17 · Cited by 96
Experience of the Eliava Institute in bacteriophage therapy
Kutateladze, M. (2015) · Virologica Sinica · doi:10.1007/s12250-014-3557-0 · Cited by 94
Kusradze, I., Karumidze, N., Rigvava, S., Dvalidze, T., Katsitadze, M., Amiranashvili, I., & Goderdzishvili, M. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01590 · Cited by 94
Metagenomic Analysis of Therapeutic PYO Phage Cocktails from 1997 to 2014
Villarroel, J., Larsen, M., Kilstrup, M., & Nielsen, M. (2017) · Viruses · doi:10.3390/v9110328 · Cited by 86
Phage Abp1 Rescues Human Cells and Mice from Infection by Pan-Drug Resistant Acinetobacter Baumannii
Yin, S., Huang, G., Zhang, Y., Jiang, B., Yang, Z., Dong, Z.-W., You, B. R., Yuan, Z., Hu, F., Zhao, Y., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000486117 · Cited by 86
Information Phage Therapy Research Should Report
Abedon, S. T. (2017) · Pharmaceuticals · doi:10.3390/ph10020043 · Cited by 81
Zhou, W., Feng, Y., & Zong, Z. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00850 · Cited by 74
Phage therapy targetingEscherichia coli—a story with no end?
Bolocan, A. S., Callanan, J., Forde, A., Ross, R. P., & Hill, C. (2016) · FEMS Microbiology Letters · doi:10.1093/femsle/fnw256 · Cited by 65
Daly, A. K. (2007) · PubMed · doi:10.25405/ncl.34631064 · Cited by 63
Olszak, T., Żarnowiec, P., Kaca, W., Danis-Wlodarczyk, K. M., Augustyniak, D., Dřevínek, P., Soyza, A. D., McClean, S., & Drulis‐Kawa, Z. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6492-6 · Cited by 63
Vahedi, A., Dallal, M. M. S., Douraghi, M., Nikkhahi, F., Rajabi, Z., Yousefi, M., & Mousavi, M. (2018) · FEMS Microbiology Letters · doi:10.1093/femsle/fny136 · Cited by 56
Rossitto, M., Fiscarelli, E. V., & Rosati, P. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00775 · Cited by 49
Yan, G., Liu, J., Ma, Q., Zhu, R., Guo, Z., Gao, C., Wang, S., Yu, L., Gu, J., Hu, D., et al. (2017) · Antonie van Leeuwenhoek · doi:10.1007/s10482-017-0912-9 · Cited by 48
Use of bacteriophages in the treatment ofPseudomonas aeruginosainfections
Soothill, J. S. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.826990 · Cited by 45
Tkhilaishvili, T., Luca, M. D., Abbandonato, G., Maiolo, E. M., Klatt, A.-B., Reuter, M., Möncke‐Buchner, E., & Trampuž, A. (2018) · Research in Microbiology · doi:10.1016/j.resmic.2018.05.010 · Cited by 45
Potential of a Lytic Bacteriophage to Disrupt Acinetobacter Baumannii Biofilms in Vitro
Liu, Y., Mi, Z., Niu, W., An, X., Yuan, X., Liu, H., Wang, Y., Feng, Y., Huang, Y., Zhang, X., et al. (2016) · Future Microbiology · doi:10.2217/fmb-2016-0104 · Cited by 39
Paving a regulatory pathway for phage therapy
Huys, I., Pirnay, J., Lavigne, R., Jennes, S., Vos, D. D., Casteels, M., & Verbeken, G. (2013) · EMBO Reports · doi:10.1038/embor.2013.163 · Cited by 38
Shiley, J. R., Comfort, K. K., & Robinson, J. B. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-017-8504-1 · Cited by 30
Cited by
Dąbrowska, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21572 · Cited by 375
Current challenges and future opportunities of phage therapy
Pires, D. P., Costa, A. R., Pinto, G., Meneses, L., & Azeredo, J. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa017 · Cited by 340
Biological control of plant diseases – What has been achieved and what is the direction?
Collinge, D. B., Jensen, D. F., Rabiey, M., Sarrocco, S., Shaw, M. W., & Shaw, R. H. (2022) · Plant Pathology · doi:10.1111/ppa.13555 · Cited by 319
Phages and their potential to modulate the microbiome and immunity
Federici, S., Nobs, S. P., & Elinav, E. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00532-4 · Cited by 222
Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18081115 · Cited by 56
Metadata
- Authors
- Furfaro, L. L., Payne, M. S., & Chang, B. J.
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2018-10-23
- Volume
- 8
- Pages
- 376-376
- ISSN
- 2235-2988 (ISSN-L)
- OpenAlex
- W2897254003
- Cited by
- 362
- References
- 63
- FWCI
- 24.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.